Contact
searchSearch
HMP Global
Login

Oncology

Featured

News
Indefinite Lenalidomide Maintenance Fails to Improve Overall Survival in Standard-Risk Multiple Myeloma
07/16/2026
Stephanie Holland
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3...
07/16/2026
Oncology
Jay Detsky, MD PhD
Videos
MRI-Guided Adaptive Radiotherapy Safely Reduces Treatment Margins in Glioblastoma
07/16/2026
Jay Detsky, MD, PhD, discusses results from the phase 2 UNITED trial showing that MRI-guided adaptive radiotherapy safely reduced treatment margins while maintaining tumor control in patients with newly diagnosed glioblastoma, supporting...
Jay Detsky, MD, PhD, discusses results from the phase 2 UNITED trial showing that MRI-guided adaptive radiotherapy safely reduced treatment margins while maintaining tumor control in patients with newly diagnosed glioblastoma, supporting...
Jay Detsky, MD, PhD, discusses...
07/16/2026
Oncology
News
Dostarlimab Meets Primary End Point in Registrational AZUR-1 Trial for dMMR/MSI-H Rectal Cancer
07/16/2026
Stephanie Holland
Interim results from the registrational phase 2 AZUR-1 trial demonstrated that dostarlimab monotherapy achieved a clinically meaningful and durable clinical complete response in patients with stage II/III mismatch...
Interim results from the registrational phase 2 AZUR-1 trial demonstrated that dostarlimab monotherapy achieved a clinically meaningful and durable clinical complete response in patients with stage II/III mismatch...
Interim results from the...
07/16/2026
Oncology
Rimas Lukas, MD
Videos
IDO1 Inhibition Combined With Radiotherapy and Nivolumab Demonstrates Safety in Newly Diagnosed Glioblastoma
07/15/2026
Rimas Lukas, MD
Rimas Lukas, MD, discusses results from a phase 1 study showing that the IDO1 inhibitor BMS-986205 combined with radiotherapy and nivolumab demonstrated a manageable safety profile and established a recommended phase 2 dose in patients with...
Rimas Lukas, MD, discusses results from a phase 1 study showing that the IDO1 inhibitor BMS-986205 combined with radiotherapy and nivolumab demonstrated a manageable safety profile and established a recommended phase 2 dose in patients with...
Rimas Lukas, MD, discusses...
07/15/2026
Oncology
Michele Milella, MD
Videos
Intratumoral Phosphorus-32 Enhances FOLFIRINOX in Locally Advanced Pancreatic Cancer
07/15/2026
Michele Milella, MD
Michele Milella, MD, discusses results from the phase 2 TRIPP-FFX trial showing that intratumoral phosphorus-32 microparticle implantation combined with FOLFIRINOX achieved high local disease control and encouraging tumor responses in...
Michele Milella, MD, discusses results from the phase 2 TRIPP-FFX trial showing that intratumoral phosphorus-32 microparticle implantation combined with FOLFIRINOX achieved high local disease control and encouraging tumor responses in...
Michele Milella, MD, discusses...
07/15/2026
Oncology
Peter Voorhees, MD
Videos
MonumenTAL-3 Demonstrates Superior Outcomes With Talquetamab-Based Combinations in Relapsed Multiple Myeloma
07/15/2026
Peter Voorhees, MD
Peter Voorhees, MD, discusses results from the phase 3 MonumenTAL-3 trial showing that talquetamab-based combinations significantly improved progression-free survival and depth of response in relapsed multiple myeloma while maintaining...
Peter Voorhees, MD, discusses results from the phase 3 MonumenTAL-3 trial showing that talquetamab-based combinations significantly improved progression-free survival and depth of response in relapsed multiple myeloma while maintaining...
Peter Voorhees, MD, discusses...
07/15/2026
Oncology
FDA Approval
FDA Approves Gedatolisib-Based Regimens for PIK3CA Wild-Type HR-Positive, HER2-Negative Advanced Breast Cancer
07/14/2026
Stephanie Holland
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for patients with PIK3CA wild-type HR-positive, HER2-negative advanced or metastatic breast cancer based on the phase 3 VIKTORIA-1 trial demonstrating...
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for patients with PIK3CA wild-type HR-positive, HER2-negative advanced or metastatic breast cancer based on the phase 3 VIKTORIA-1 trial demonstrating...
The FDA approved gedatolisib in...
07/14/2026
Oncology
FDA Approval
FDA Grants Traditional Approval to Selpercatinib for RET Fusion-Positive Solid Tumors
07/14/2026
Stephanie Holland
The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-positive solid tumors based on durable responses observed across multiple tumor types in the LIBRETTO-001...
The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-positive solid tumors based on durable responses observed across multiple tumor types in the LIBRETTO-001...
The FDA granted traditional...
07/14/2026
Oncology
Annalice Gandini, IRCCS
Videos
Real-World Neoadjuvant Immunotherapy Demonstrates High Response Rates in dMMR/MSI Colorectal Cancer
07/14/2026
Annalice Gandini
Annalice Gandini, IRCCS, discusses results from the real-world AGEO-NEO-MSI study which demonstrated that neoadjuvant immunotherapy produced high complete response rates in patients with nonmetastatic dMMR/MSI-H colorectal cancer while...
Annalice Gandini, IRCCS, discusses results from the real-world AGEO-NEO-MSI study which demonstrated that neoadjuvant immunotherapy produced high complete response rates in patients with nonmetastatic dMMR/MSI-H colorectal cancer while...
Annalice Gandini, IRCCS,...
07/14/2026
Oncology
News
De-escalated Paclitaxel, Trastuzumab, and Pertuzumab Yield Excellent Long-Term Outcomes in HER2-Positive Breast Cancer
07/14/2026
Stephanie Holland
A prespecified analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab produced excellent 5-year outcomes in stage II to III HER2-positive breast cancer, while ultrasensitive...
A prespecified analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab produced excellent 5-year outcomes in stage II to III HER2-positive breast cancer, while ultrasensitive...
A prespecified analysis of the...
07/14/2026
Oncology
FDA Approval
FDA Approves Pegfilgrastim Biosimilar ENNUMO for the Prevention of Febrile Neutropenia and Treatment of Acute Radiation Syndrome
07/13/2026
Stephanie Holland
The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...
The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...
The FDA approved ENNUMO, a...
07/13/2026
Oncology

Videos

Jay Detsky, MD PhD
Videos
MRI-Guided Adaptive Radiotherapy Safely Reduces Treatment Margins in Glioblastoma
07/16/2026
Jay Detsky, MD, PhD, discusses results from the phase 2 UNITED trial showing that MRI-guided adaptive radiotherapy safely reduced treatment margins while maintaining tumor control in patients with newly diagnosed glioblastoma, supporting...
Jay Detsky, MD, PhD, discusses results from the phase 2 UNITED trial showing that MRI-guided adaptive radiotherapy safely reduced treatment margins while maintaining tumor control in patients with newly diagnosed glioblastoma, supporting...
Jay Detsky, MD, PhD, discusses...
07/16/2026
Oncology
Rimas Lukas, MD
Videos
IDO1 Inhibition Combined With Radiotherapy and Nivolumab Demonstrates Safety in Newly Diagnosed Glioblastoma
07/15/2026
Rimas Lukas, MD
Rimas Lukas, MD, discusses results from a phase 1 study showing that the IDO1 inhibitor BMS-986205 combined with radiotherapy and nivolumab demonstrated a manageable safety profile and established a recommended phase 2 dose in patients with...
Rimas Lukas, MD, discusses results from a phase 1 study showing that the IDO1 inhibitor BMS-986205 combined with radiotherapy and nivolumab demonstrated a manageable safety profile and established a recommended phase 2 dose in patients with...
Rimas Lukas, MD, discusses...
07/15/2026
Oncology
Michele Milella, MD
Videos
Intratumoral Phosphorus-32 Enhances FOLFIRINOX in Locally Advanced Pancreatic Cancer
07/15/2026
Michele Milella, MD
Michele Milella, MD, discusses results from the phase 2 TRIPP-FFX trial showing that intratumoral phosphorus-32 microparticle implantation combined with FOLFIRINOX achieved high local disease control and encouraging tumor responses in...
Michele Milella, MD, discusses results from the phase 2 TRIPP-FFX trial showing that intratumoral phosphorus-32 microparticle implantation combined with FOLFIRINOX achieved high local disease control and encouraging tumor responses in...
Michele Milella, MD, discusses...
07/15/2026
Oncology
Peter Voorhees, MD
Videos
MonumenTAL-3 Demonstrates Superior Outcomes With Talquetamab-Based Combinations in Relapsed Multiple Myeloma
07/15/2026
Peter Voorhees, MD
Peter Voorhees, MD, discusses results from the phase 3 MonumenTAL-3 trial showing that talquetamab-based combinations significantly improved progression-free survival and depth of response in relapsed multiple myeloma while maintaining...
Peter Voorhees, MD, discusses results from the phase 3 MonumenTAL-3 trial showing that talquetamab-based combinations significantly improved progression-free survival and depth of response in relapsed multiple myeloma while maintaining...
Peter Voorhees, MD, discusses...
07/15/2026
Oncology
Annalice Gandini, IRCCS
Videos
Real-World Neoadjuvant Immunotherapy Demonstrates High Response Rates in dMMR/MSI Colorectal Cancer
07/14/2026
Annalice Gandini
Annalice Gandini, IRCCS, discusses results from the real-world AGEO-NEO-MSI study which demonstrated that neoadjuvant immunotherapy produced high complete response rates in patients with nonmetastatic dMMR/MSI-H colorectal cancer while...
Annalice Gandini, IRCCS, discusses results from the real-world AGEO-NEO-MSI study which demonstrated that neoadjuvant immunotherapy produced high complete response rates in patients with nonmetastatic dMMR/MSI-H colorectal cancer while...
Annalice Gandini, IRCCS,...
07/14/2026
Oncology
Videos
ctDNA MRD Testing in Lymphoma: Clinical Utility and Applications
07/06/2026
David Russler-Germain, MD, PhD
Dr David Russler-Germain explains how ctDNA–based minimal residual disease testing is helping refine post-treatment risk stratification, detect relapse earlier, and guide more personalized treatment decisions in diffuse large B-cell lymphoma,...
Dr David Russler-Germain explains how ctDNA–based minimal residual disease testing is helping refine post-treatment risk stratification, detect relapse earlier, and guide more personalized treatment decisions in diffuse large B-cell lymphoma,...
Dr David Russler-Germain...
07/06/2026
Oncology
Videos
ctDNA MRD Testing in Lymphoma: What It Is and How It Works
07/06/2026
David Russler-Germain, MD, PhD
Dr David Russler-Germain explains how ctDNA–based MRD testing enables highly sensitive, personalized detection of residual disease and is emerging as a valuable tool for assessing treatment response, predicting relapse risk, and guiding...
Dr David Russler-Germain explains how ctDNA–based MRD testing enables highly sensitive, personalized detection of residual disease and is emerging as a valuable tool for assessing treatment response, predicting relapse risk, and guiding...
Dr David Russler-Germain...
07/06/2026
Oncology
Videos
Detecting Residual Disease in Lymphoma: Current and Emerging Tools
07/06/2026
David Russler-Germain, MD, PhD
Dr David Russler-Germain explains how ctDNA–based MRD testing is emerging as a more sensitive and accurate tool than PET/CT imaging for predicting relapse risk and assessing remission in DLBCL.
Dr David Russler-Germain explains how ctDNA–based MRD testing is emerging as a more sensitive and accurate tool than PET/CT imaging for predicting relapse risk and assessing remission in DLBCL.
Dr David Russler-Germain...
07/06/2026
Oncology
Gunnar Folprecht, MD, PhD
Videos
Clinical Utility of ctDNA-Guided Adjuvant Therapy in Stage II Colon Cancer
07/01/2026
Gunnar Folprecht, MD, PhD
Gunnar Folprecht, MD, PhD, discusses results from the CIRCULATE trial showing that tumor-informed circulating tumor DNA testing identified patients with stage II colon cancer who derived significant benefit from adjuvant chemotherapy,...
Gunnar Folprecht, MD, PhD, discusses results from the CIRCULATE trial showing that tumor-informed circulating tumor DNA testing identified patients with stage II colon cancer who derived significant benefit from adjuvant chemotherapy,...
Gunnar Folprecht, MD, PhD,...
07/01/2026
Oncology
Marco Ruella, MD
Videos
Ten-Year Tisagenlecleucel Outcomes Highlight Lasting Remissions in Relapsed or Refractory B-Cell Lymphoma
07/01/2026
Marco Ruella, MD
Marco Ruella, MD, discusses 10-year follow-up data showing that tisagenlecleucel produced durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, supporting the long-term curative...
Marco Ruella, MD, discusses 10-year follow-up data showing that tisagenlecleucel produced durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, supporting the long-term curative...
Marco Ruella, MD, discusses...
07/01/2026
Oncology

Insights From the ASCO Annual Meeting

News
First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia
07/09/2026
Stephanie Holland
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase...
07/09/2026
Oncology
News
Imetelstat Maintains Overall Survival Advantage Over Best Available Therapy in JAK Inhibitor–Relapsed or Refractory Myelofibrosis
07/09/2026
Stephanie Holland
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc...
07/09/2026
Oncology
Ramaswamy Govindan, MD
Videos
Adjuvant Erlotinib Following Complete Resection of EGFR-Mutant Non-Small Cell Lung Cancer Improves Disease Free Survival But Not Overall Survival
06/29/2026
Ramaswamy Govindan, MD
Ramaswamy Govindan, MD, discusses the final overall survival results from the Alliance A081105 ALCHEMIST trial evaluating adjuvant erlotinib after complete resection of stage IB-IIIA EGFR-mutant non-small cell lung cancer (NSCLC). Originally...
Ramaswamy Govindan, MD, discusses the final overall survival results from the Alliance A081105 ALCHEMIST trial evaluating adjuvant erlotinib after complete resection of stage IB-IIIA EGFR-mutant non-small cell lung cancer (NSCLC). Originally...
Ramaswamy Govindan, MD,...
06/29/2026
Oncology
Erika Hamilton, MD
Videos
Tucatinib Demonstrates Consistent Benefit Across First-Line HER2-Positive Metastatic Breast Cancer Populations
06/26/2026
Erika Hamilton, MD
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses...
06/26/2026
Oncology
Bjørn Henning Grønberg, MD, PhD
Videos
Concurrent Thoracic Radiotherapy, Platinum/Etoposide Chemotherapy, and Durvalumab Immunotherapy Does Not Improve Outcomes in Extensive-Stage Small Cell Lung Cancer
06/26/2026
Bjørn Henning Grønberg, MD, PhD
Bjørn Henning Grønberg, MD, PhD, professor and consultant in oncology at the Norwegian University of Science and Technology and St. Olavs Hospital in Trondheim, Norway, discusses results from a phase 3 randomized trial evaluating the addition...
Bjørn Henning Grønberg, MD, PhD, professor and consultant in oncology at the Norwegian University of Science and Technology and St. Olavs Hospital in Trondheim, Norway, discusses results from a phase 3 randomized trial evaluating the addition...
Bjørn Henning Grønberg, MD, PhD,...
06/26/2026
Oncology
Peter O’Donnell, MD
Videos
Health-Related Quality of Life Preserved with Neoadjuvant and Adjuvant Enfortumab Vedotin plus Pembrolizumab in Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
06/26/2026
Peter O'Donnell, MD
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the...
06/26/2026
Oncology
Sanjay Popat, PhD, FRCP
Videos
Pralsetinib Shows Improved Response in RET Fusion–Positive Advanced or Metastatic Non–Small Cell Lung Cancer
06/25/2026
Sanjay Popat, PhD, FRCP
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical...
06/25/2026
Oncology
Walter Weber, MD
Videos
Prepectoral Implant Placement Improves Long-Term Quality of Life After Breast Reconstruction
06/24/2026
Walter Weber, MD
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses...
06/24/2026
Oncology
Timothy Cloughesy, MD
Videos
Vorasidenib Maintains Durable Clinical Benefit With Consistent Safety in IDH-Mutated Glioma
06/24/2026
Timothy Cloughesy, MD
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
Giredestrant Improves Outcomes Regardless of Menopausal Status in Early Breast Cancer
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology

Insights From the ESMO Congress

Stephen Freedland, MD
Videos
Enzalutamide Plus Androgen Deprivation Therapy in Biochemically Recurrent Prostate Cancer
12/02/2025
Stephen J. Freedland, MD
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses...
12/02/2025
Oncology
Brian Slomovitz, MD
Videos
Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
12/02/2025
Brian M. Slomovitz, MD, MS
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
12/02/2025
Oncology
Pasi Jänne, MD, PhD
Videos
Osimertinib Plus Chemotherapy Provides Broad Survival Benefit in EGFR-Mutant NSCLC
12/02/2025
Pasi Jänne, MD, PhD
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses...
12/02/2025
Oncology
David Goldstein, MD
Videos
Regorafenib Plus Nivolumab Fails to Improve Outcomes in Gastric or Gastroesophageal Cancer
12/02/2025
David Goldstein, MD
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses...
12/02/2025
Oncology
Sara Lonardi, MD
Videos
Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
11/13/2025
Sara Lonardi, MD
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
Janice Mehnert, MD
Videos
Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma
11/10/2025
Janice Mehnert, MD
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses...
11/10/2025
Oncology
Nima Nabavizadeh, MD
Videos
MCED Blood Test Detects Cancer Early With High Accuracy
11/10/2025
Nima Nabavizadeh, MD
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses...
11/10/2025
Oncology
Maria De Santis, MD
Videos
Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer
11/10/2025
Maria De Santis, MD
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses...
11/10/2025
Oncology
Dean Fennell, MD, PhD
Videos
Intratumor Heterogeneity Predicts Niraparib Benefit in Relapsed Mesothelioma
11/10/2025
Dean Fennell, MD, PhD
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses...
11/10/2025
Oncology

Live Meetings

Recent News

News
Indefinite Lenalidomide Maintenance Fails to Improve Overall Survival in Standard-Risk Multiple Myeloma
07/16/2026
Stephanie Holland
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3...
07/16/2026
Oncology
News
Dostarlimab Meets Primary End Point in Registrational AZUR-1 Trial for dMMR/MSI-H Rectal Cancer
07/16/2026
Stephanie Holland
Interim results from the registrational phase 2 AZUR-1 trial demonstrated that dostarlimab monotherapy achieved a clinically meaningful and durable clinical complete response in patients with stage II/III mismatch...
Interim results from the registrational phase 2 AZUR-1 trial demonstrated that dostarlimab monotherapy achieved a clinically meaningful and durable clinical complete response in patients with stage II/III mismatch...
Interim results from the...
07/16/2026
Oncology
FDA Approval
FDA Approves Gedatolisib-Based Regimens for PIK3CA Wild-Type HR-Positive, HER2-Negative Advanced Breast Cancer
07/14/2026
Stephanie Holland
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for patients with PIK3CA wild-type HR-positive, HER2-negative advanced or metastatic breast cancer based on the phase 3 VIKTORIA-1 trial demonstrating...
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for patients with PIK3CA wild-type HR-positive, HER2-negative advanced or metastatic breast cancer based on the phase 3 VIKTORIA-1 trial demonstrating...
The FDA approved gedatolisib in...
07/14/2026
Oncology
FDA Approval
FDA Grants Traditional Approval to Selpercatinib for RET Fusion-Positive Solid Tumors
07/14/2026
Stephanie Holland
The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-positive solid tumors based on durable responses observed across multiple tumor types in the LIBRETTO-001...
The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-positive solid tumors based on durable responses observed across multiple tumor types in the LIBRETTO-001...
The FDA granted traditional...
07/14/2026
Oncology
News
De-escalated Paclitaxel, Trastuzumab, and Pertuzumab Yield Excellent Long-Term Outcomes in HER2-Positive Breast Cancer
07/14/2026
Stephanie Holland
A prespecified analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab produced excellent 5-year outcomes in stage II to III HER2-positive breast cancer, while ultrasensitive...
A prespecified analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab produced excellent 5-year outcomes in stage II to III HER2-positive breast cancer, while ultrasensitive...
A prespecified analysis of the...
07/14/2026
Oncology
FDA Approval
FDA Approves Pegfilgrastim Biosimilar ENNUMO for the Prevention of Febrile Neutropenia and Treatment of Acute Radiation Syndrome
07/13/2026
Stephanie Holland
The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...
The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...
The FDA approved ENNUMO, a...
07/13/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Mezigdomide Combination in Relapsed or Refractory Multiple Myeloma
07/13/2026
Stephanie Holland
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug...
07/13/2026
Oncology
News
Trastuzumab Rezetecan Improves Progression-Free Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
07/10/2026
Stephanie Holland
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase...
07/10/2026
Oncology
FDA Approval
FDA Approves Subcutaneous Isatuximab Across Multiple Indications for Patients With Multiple Myeloma
07/10/2026
Emily Estrada
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
The FDA has approved...
07/10/2026
Oncology
News
Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study...
07/09/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use